Starting from a benzazepine sulfonamide 5-HT6 receptor antagonist lead with limited brain penetration, application of a strategy of conformational constraint and reduction of hydrogen bond donor count led to a novel series of tricyclic derivatives with high 5-HT6 receptor affinity and excellent brain:blood ratios.